2024
Correlation of TILs indices generated by visual review and digital computational algorithm with outcomes from preoperative chemotherapy for TNBC in TBCRC 030.
Nader Marta G, Chu X, Mukhopadhyay S, Abramson V, Brufsky A, Stringer-Reasor E, Dent S, Traina T, Carey L, Rimawi M, Specht J, Miller K, Santa-Maria C, Dasgupta T, Binboğa Kurt B, Tayob N, Krop I, Tung N, Schnitt S, Mayer E. Correlation of TILs indices generated by visual review and digital computational algorithm with outcomes from preoperative chemotherapy for TNBC in TBCRC 030. Journal Of Clinical Oncology 2024, 42: 555-555. DOI: 10.1200/jco.2024.42.16_suppl.555.Peer-Reviewed Original ResearchTriple negative breast cancerTumor-infiltrating lymphocytesArea under the curveEvaluation of tumor-infiltrating lymphocytesCore needle biopsyNeoadjuvant chemotherapyPredictive of responseOdds ratioReceiver operating characteristicImmune microenvironmentEarly-stage triple negative breast cancerPre-treatment core needle biopsyPrediction of response to NACBaseline tumor-infiltrating lymphocytesEvaluate tumor-infiltrating lymphocytesStromal tumor-infiltrating lymphocytesResponse to NACTumor-infiltrating lymphocyte scoresResponse to neoadjuvant chemotherapyImmune responseCombined immune responseNegative breast cancerH&E-stained slidesCell cycle aberrationsCell cycle signature
2020
TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial).
Tung N, Arun B, Hacker MR, Hofstatter E, Toppmeyer DL, Isakoff SJ, Borges V, Legare RD, Isaacs C, Wolff AC, Marcom PK, Mayer EL, Lange PB, Goss AJ, Jenkins C, Krop IE, Winer EP, Schnitt SJ, Garber JE. TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial). Journal Of Clinical Oncology 2020, 38: 1539-1548. PMID: 32097092, PMCID: PMC8462533, DOI: 10.1200/jco.19.03292.Peer-Reviewed Original ResearchConceptsHER2-negative breast cancerTriple-negative breast cancerResidual cancer burden scoreBreast cancerDoxorubicin-cyclophosphamideRisk ratioStage IPathologic complete response rateHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Single-agent cisplatinComplete response ratePhase II studyPhase II trialGrowth factor receptor 2Positive breast cancerNegative breast cancerFactor receptor 2CT1-3II trialII studyNodal involvementPCR rateNegative diseasePathologic response
2017
A phase I study of PF-06647263, a novel EFNA4-ADC, in patients with metastatic triple negative breast cancer.
Garrido-Laguna I, Krop I, Burris H, Hamilton E, Braiteh F, Weise A, Abu-Khalaf M, Zopf C, Lakshminarayanan M, Holland J, Baffa R, Hong D, Hassan R. A phase I study of PF-06647263, a novel EFNA4-ADC, in patients with metastatic triple negative breast cancer. Journal Of Clinical Oncology 2017, 35: 2511-2511. DOI: 10.1200/jco.2017.35.15_suppl.2511.Peer-Reviewed Original ResearchTriple-negative breast cancerAdverse eventsNegative breast cancerExpansion cohortPartial responseBreast cancerMetastatic triple-negative breast cancerAnti-drug antibody developmentCommon adverse eventsDuration of treatmentAnti-tumor activityVivo preclinical studiesQ3w scheduleQW scheduleRECIST responseAdvanced malignanciesMucosal inflammationObjective responseDose escalationTNBC patientsTumor regressionTNBC modelsPreclinical studiesCommon treatmentPK data
2013
Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry
Kluk MJ, Ashworth T, Wang H, Knoechel B, Mason EF, Morgan EA, Dorfman D, Pinkus G, Weigert O, Hornick JL, Chirieac LR, Hirsch M, Oh DJ, South AP, Leigh IM, Pourreyron C, Cassidy AJ, DeAngelo DJ, Weinstock DM, Krop IE, Dillon D, Brock JE, Lazar AJ, Peto M, Cho RJ, Stoeck A, Haines BB, Sathayanrayanan S, Rodig S, Aster JC. Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry. PLOS ONE 2013, 8: e67306. PMID: 23825651, PMCID: PMC3688991, DOI: 10.1371/journal.pone.0067306.Peer-Reviewed Original ResearchConceptsCell lymphomaNotch1 activationNOTCH1 mutationsPeripheral T-cell lymphomaNon-small cell lung carcinomaLymphoblastic leukemia/lymphomaTriple-negative breast cancerLarge B-cell lymphomaSelection of patientsChronic lymphocytic leukemia cellsT-cell lymphomaCell lung carcinomaNegative breast cancerChronic lymphocytic leukemiaLeukemia/lymphomaB-cell lymphomaMantle cell lymphomaB-cell tumorsRole of Notch1Lymphocytic leukemia cellsLymph nodesAngioimmunoblastic lymphomaCell tumorsClinical trialsOvarian carcinoma
2011
PD05-07: Prospective Validation and Characterization of HER2 Positive Circulating Tumor Cells in Patients with HER2 Negative Metastatic Breast Cancer.
Olson E, Flores L, Najita J, Curley C, Jeong J, Murray K, Savoie J, Winer E, Krop I. PD05-07: Prospective Validation and Characterization of HER2 Positive Circulating Tumor Cells in Patients with HER2 Negative Metastatic Breast Cancer. Cancer Research 2011, 71: pd05-07-pd05-07. DOI: 10.1158/0008-5472.sabcs11-pd05-07.Peer-Reviewed Original ResearchHER2-positive CTCsMetastatic breast cancerHER2-negative metastatic breast cancerNegative metastatic breast cancerHER2-negative CTCsER-positive diseasePositive CTCsBreast cancerDetectable CTCsLobular histologyPositive diseaseNegative CTCsHER2 amplificationProspective validationHER2-Positive Circulating Tumor CellsHER2-negative breast cancerCEP17 ratioTumor cellsInitial screeningMajority of ptsNegative breast cancerHER2/CEP17 ratioCirculating Tumor CellsDuctal histologyBaseline characteristics